Clinical Trial

SBRT for Liver Tumors, Liver Metastases, and Pancreatic Tumors

Completed
View on ClinicalTrials.gov →
Summary
This prospective observational study evaluates the safety and effectiveness of stereotactic body radiotherapy (SBRT) for liver tumors, liver metastases, and pancreatic tumors. The study focuses on systematic monitoring and optimization of the SBRT treatment process, including adherence to the implemented protocol, with the aim of simplifying methods while maintaining treatment safety.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-06; most recent amendment 2026-02-16.
Trial Details
NCT Number NCT07407257
Lead Sponsor Institute of Oncology Ljubljana
Conditions Liver Neoplasms, Liver Metastases, Pancreatic Neoplasms
Enrollment 65 participants
Start Date 2019-01-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-18